New Study Finds That UCLA and Other Top Research Universities Have Done Little To Make New Drugs Accessible

Keerthi Vedantam

Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

New Study Finds That UCLA and Other Top Research Universities Have Done Little To Make New Drugs Accessible

Despite gobbling up taxpayer dollars, UCLA and other top U.S. research universities are not doing enough to make drugs and medical devices financially accessible to people in low-income countries, a new report found.


Universities Allied for Essential Medicines, a student-run nonprofit focused on making costly medicines cheaper worldwide, used public data and a survey to rank 60 universities on their dedication to improve health disparities in low-income countries.

UCLA and 16 other top public universities that develop drug treatments got a D-minus rating for centering much of their research around private companies and failing to prioritize global health. The report also found the university failed to fund many projects that would help treat neglected diseases most common in low-income countries.

Avani Reddy, a neuroscience student at UCLA and one a member of UAEM, said the group compiled the report to ensure that her school and other universities were developing drugs at "sustainable prices and not obnoxious prices."

Georgetown and Harvard ranked highest with a B- while other UC system schools, including San Francisco and Davis, also got Ds, while Irvine got a F.

UCLA declined to respond to questions about the study, but said the university did not participate. UAEM ranked universities that did not respond lower than those that did.

"It should be that that research is accessible to people," said Devika Shenoy, a UCLA student and UAEM member studying human biology and society.

The 20-year-old student organization was born out of an effort by Yale University students to make an HIV/AIDS drug developed at the school and distributed by Bristol-Myers Squibb cheaper for low-income countries by allowing for the production of generics.

UCLA received $840 million in federal dollars for the 2019-2020 fiscal year, much of which went towards the medical and life sciences schools.

UAEM wants major federally funded research universities to focus on the issues big pharma companies find less profitable, like when Johns Hopkins surrendered a tuberculosis drug to a United Nations-supported organization to distribute the drug royalty-free. These schools, UAEM argues, should serve a larger public good in part because the public is paying for the research.

"Universities hold influence to leverage their significant contribution in biomedical research to advance global access to essential medicines and health technologies," the UAEM report said, pointing to the fact that one-third of new medicines originate in universities, according to a 2010 report.

UCLA has come under fire for drug access before. In 2016, the school sold a drug it developed to treat prostate cancer to Royalty Pharma. When a generic drug company in India tried to reproduce it, the school filed a patent claim, sparking protests. Ultimately, UCLA prevailed. But the incident highlights the pressure public-funded research universities are under to make their discoveries available and the competing demand from a market that relies on them.

Low and middle-income countries "may not have access to those resources to invest in R&D the way that schools like UCLA can in order to ensure that global public health needs are really being prioritized," Shenoy said.

COVID has brought these issues to the forefront. Oxford University originally developed its COVID-19 vaccine with the promise it would be open source so it could be distributed in low-income countries at a low cost or for free. Instead, it became the AstraZenca vaccine after the Gates Foundation brokered a deal between the two parties.

Meanwhile, only 0.1% of COVID-19 vaccines have made it to low-income countries. In 2020, organizations like Amnesty International warned that many in low-income countries would not have access to patented vaccines owned by wealthier countries. Vaccines specifically made with cheaper and accessible materials have just begun clinical trials, and pharma giant Pfizer will start testing a freeze-dried vaccine that can withstand higher temperatures this month.

Universities play a sizable role in the pharmaceutical pipeline, especially in preclinical development, according to Bill Bolding, a senior analyst at Provident Healthcare Partners. Venture firms and pharma companies rarely start investing in bioscience companies until there is proof of concept, much of which is created in university labs.

"Usually what you're seeing in the preclinical level is you're seeing like some kind of chemical reaction or proof of some kind of technology, in vitro," Bolding said.

Subscribe to our newsletter to catch every headline.

Cadence

E-Scooter Companies Are Quietly Changing Their Low-Income Programs in LA

Maylin Tu
Maylin Tu is a freelance writer who lives in L.A. She writes about scooters, bikes and micro-mobility. Find her hovering by the cheese at your next local tech mixer.
E-Scooter Companies Are Quietly Changing Their Low-Income Programs in LA
Photo by Maylin Tu

When Lime launched in Los Angeles in 2018, the company offered five free rides per day to low-income riders, so long as they were under 30 minutes each.

But in early May, that changed. Rides under 30 minutes now cost low-income Angelenos a flat rate of $1.25. As for the five free rides per day, that program ended December 2021 and was replaced by a rate of $0.50 fee to unlock e-scooters, plus $0.07 per minute (and tax).

Lime isn’t alone. Lyft and Spin have changed the terms of their city-mandated low-income programs. Community advocates say they were left largely unaware.

Read more Show less

Faraday Future Reveals Only 401 Pre-Orders For Its First Electric Car

David Shultz

David Shultz is a freelance writer who lives in Santa Barbara, California. His writing has appeared in The Atlantic, Outside and Nautilus, among other publications.

Faraday Future Reveals Only 401 Pre-Orders For Its First Electric Car
Courtesy of Faraday Future

Electric vehicle hopeful Faraday Future has had no shortage of drama—from alleged securities law violations to boardroom shake-ups—on its long and circuitous path to actually producing a car. And though the Gardena-based company looked to have turned a corner by recently announcing plans to launch its first vehicle later this year, Faraday’s quarterly earnings report this week revealed that demand for that car has underwhelmed—to say the least.

Read more Show less

Meet CropSafe, the Agtech Startup Helping Farmers Monitor Their Fields

David Shultz

David Shultz is a freelance writer who lives in Santa Barbara, California. His writing has appeared in The Atlantic, Outside and Nautilus, among other publications.

Meet CropSafe, the Agtech Startup Helping Farmers Monitor Their Fields
Courtesy of CropSafe.

This January, John McElhone moved to Santa Monica from, as he described it, “a tiny farm in the absolute middle of nowhere” in his native Northern Ireland, with the goal of growing the crop-monitoring tech startup he founded.

It looks like McElhone’s big move is beginning to pay off: His company, CropSafe, announced a $3 million seed funding round on Tuesday that will help it develop and scale its remote crop-monitoring capabilities for farmers. Venture firm Elefund led the round and was joined by investors Foundation Capital, Global Founders Capital, V1.VC and Great Oaks Capital, as well as angel investors Cory Levy, Josh Browder and Charlie Songhurst. The capital will go toward growing CropSafe’s six-person engineering team and building up its new U.S. headquarters in Santa Monica.

Read more Show less
RELATEDEDITOR'S PICKS
LA TECH JOBS
interchangeLA
Trending